Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-1: Axicabtagene Ciloleucel in Refractory Aggressive Non-Hodgkin Lymphoma
NCT02348216Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Apr 2015
- Primary completion
- Jul 2023
- Modality
- CAR-T Cells
- Countries
- 6
01
Overview
Phase 2, open-label trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL) and 1 more (7 arms), sponsored by Kite Pharma. Primary endpoints: Dose Limiting Toxicities at 30 days, Overall Response Rate up to 7.7 years and 1 more. Started Apr 2015; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)Transformed Follicular Lymphoma (tFL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT02348216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348216.